E-Mail
Amsterdam, April 29, 2021 - The clinical presentation and underlying biology of Parkinson s disease (PD) varies significantly, but attempts to cluster cases into a limited number of subtypes have questionable applicability and relevance, reports the international Task Force for PD Subtypes in the
Journal of Parkinson s Disease. Their systematic review of studies reporting a subtyping system for the first time concludes that new approaches are needed that acknowledge the individual nature of the disease and are more aligned with personalized medicine.
In 2018, the International Parkinson s Disease and Movement Disorders Society (MDS) convened the Task Force for PD Subtypes to critically appraise available PD subtyping studies and to provide guidance for the design and conduct of future studies.
NIH-funded study in mice suggests lymphatic boost could help reduce amyloid buildup.
Study of mouse brain shows the meningeal lymphatics system (purple and pink) could help reduce amyloid. Sandro Da Mesquita, Ph.D.
Enhancing the brainâs lymphatic system when administering immunotherapies may lead to better clinical outcomes for Alzheimerâs disease patients, according to a new study in mice. Results published April 28 in
Nature suggest that treatments such as the immunotherapies BAN2401 or aducanumab might be more effective when the brainâs lymphatic system can better drain the amyloid-beta protein that accumulates in the brains of those living with Alzheimerâs. Major funding for the research was provided by the National Institute on Aging (NIA), part of the National Institutes of Health, and all study data is now freely available to the broader scientific community.
HIN
Enhancing the brain’s lymphatic system when administering immunotherapies may lead to better clinical outcomes for Alzheimer’s disease patients, according to a new study in mice. Results published April 28 in Nature suggest that treatments such as the immunotherapies BAN2401 or aducanumab might be more effective when the brain’s lymphatic system can better drain the amyloid-beta protein that accumulates in the brains of those living with Alzheimer’s. Major funding for the research was provided by the National Institute on Aging (NIA), part of the National Institutes of Health, and all study data is now freely available to the broader scientific community.
(0)
DGAP-News: AFFiRiS AG / Key word(s): Conference/Study
AFFiRiS AG: Positive preclinical in vivo results with AFFiRiS antibody mAB C6-17 to treat Huntington s disease to be presented at the 16th Annual Huntington s Disease Therapeutics Conference
27.04.2021 / 09:00
Positive preclinical
in vivo results with AFFiRiS antibody mAB C6-17 to treat Huntington s disease to be presented at the 16
th Annual Huntington s Disease Therapeutics Conference
- Monoclonal antibody C6-17 designed to target mutant huntingtin protein (mtHTT) and to reduce spread of Huntington s disease pathology
- Human mtHTT transgenic mice treated with mAB C6-17 showed significantly reduced mtHTT levels in peripheral organs and central nervous system and displayed improved motor performance
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17 to treat Huntington’s .
AFFiRiS AGApril 27, 2021 GMT
Monoclonal antibody C6-17 designed to target mutant huntingtin protein (mtHTT) and to reduce spread of Huntington’s disease pathology
Human mtHTT transgenic mice treated with mAB C6-17 showed significantly reduced mtHTT levels in peripheral organs and central nervous system and displayed improved motor performance Results set the ground for AFFiRiS’ potential first-in-class antibody-based systemic therapeutic modalities targeting mtHTT directly
VIENNA, Austria, April 27, 2021 (GLOBE NEWSWIRE) AFFiRiS, a clinical-stage biotechnology company developing novel disease-modifying specific immunotherapies, announces today the presentation of